Q3 Earnings Forecast for Amgen Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised Amgen's Q3 2025 earnings per share estimate down to $5.13, from a previous estimate of $5.40, reflecting a cautious outlook.
• Amgen recently reported a net margin of 18.96% and a revenue of $9.18 billion for the last quarter, which surpassed analysts' expectations.
• The company has declared a quarterly dividend of $2.38, representing an annualized yield of 3.3%, with payment scheduled for September 12th.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Analysts at Leerink Partnrs reduced their Q3 2025 EPS estimates for Amgen in a research report issued to clients and investors on Tuesday, August 5th. Leerink Partnrs analyst D. Risinger now anticipates that the medical research company will post earnings per share of $5.13 for the quarter, down from their prior forecast of $5.40. The consensus estimate for Amgen's current full-year earnings is $20.62 per share. Leerink Partnrs also issued estimates for Amgen's Q4 2025 earnings at $5.00 EPS, FY2025 earnings at $21.11 EPS and FY2026 earnings at $20.32 EPS.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. During the same period last year, the business earned $4.97 earnings per share. The business's quarterly revenue was up 9.4% on a year-over-year basis.

Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald reiterated a "neutral" rating and set a $305.00 price target on shares of Amgen in a research report on Tuesday, June 24th. Piper Sandler restated an "overweight" rating and issued a $328.00 target price on shares of Amgen in a report on Friday, June 27th. Mizuho raised their target price on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a report on Wednesday, May 7th. William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Finally, UBS Group cut their target price on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating on the stock in a report on Wednesday. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $303.76.

Amgen Price Performance

NASDAQ AMGN traded up $3.53 on Thursday, reaching $288.23. 1,802,960 shares of the company's stock traded hands, compared to its average volume of 2,050,777. Amgen has a 12 month low of $253.30 and a 12 month high of $339.17. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.88. The stock has a 50-day simple moving average of $293.23 and a 200 day simple moving average of $292.71. The stock has a market cap of $155.17 billion, a PE ratio of 23.57, a P/E/G ratio of 2.47 and a beta of 0.49.

Hedge Funds Weigh In On Amgen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC purchased a new position in shares of Amgen in the 1st quarter worth about $25,000. First Pacific Financial raised its position in shares of Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after purchasing an additional 67 shares during the last quarter. CBIZ Investment Advisory Services LLC raised its position in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock worth $29,000 after purchasing an additional 85 shares during the last quarter. Legacy Investment Solutions LLC purchased a new position in shares of Amgen in the 2nd quarter worth about $27,000. Finally, Pinney & Scofield Inc. purchased a new position in shares of Amgen in the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.76% of the company's stock.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.3%. Amgen's dividend payout ratio (DPR) is currently 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.